Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial

@inproceedings{Shi2017EffectOE,
  title={Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial},
  author={Xiulin Shi and Yalin Shi and Ning Chen and Mingzhu Lin and Weijuan Su and Huijie Zhang and Changqin Liu and Haiqu Song and Fangsen Xiao and Peiying Huang and Liying Wang and Wei Liu and Jinyang Zeng and Bing Yan and Qi Liu and Suhuan Liu and Shuyu Yang and Xiaoying Li and Zhibin Li and Xue-jun Li},
  booktitle={Scientific Reports},
  year={2017}
}
Early short-term intensive insulin (STII) therapy can induce drug-free glycemic remission for up to 1 year in half of newly diagnosed type 2 diabetic mellitus (T2DM) patients. Whether exenatide following STII therapy will induce higher long-term glycaemic remission is currently unknown. To assess the effect of STII+ exenatide therapy, compared with STII… CONTINUE READING